Pharmafile Logo
Pharmafocus logo
Advanced Search

Neurocrine Biosciences

Showing 4 posts of 4 posts found.

robina-weermeijer-so1l3jsdd3y-unsplash_2

Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …

News

FDA approves first endometriosis pain management drug in a decade

July 25, 2018
Research and Development, Sales and Marketing AbbVie, FDA, Neurocrine Biosciences, endometriosis, pharma

The FDA has confirmed its approval of AbbVie and Neurocrine Biosciences’ Orilissa (elagolix), a nonpeptide small molecule gonadotropin-releasing hormone (GnRH) …

News
shutterstock_212432119

Neurocrine’s Ingrezza flops in Tourette’s for second time

May 25, 2017
Research and Development, Sales and Marketing Neurocrine Biosciences, tourette's

Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …

News
fdaoutsideweb

FDA approves first and only tardive dyskinesia treatment

April 12, 2017
Research and Development, Sales and Marketing FDA, Neurocrine Biosciences, tardive dyskinesia

US patients suffering with tardive dyskinesia (TD) will see access to the first approved treatment in the country with the …

News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024